Innocutis Company Profile
Innocutis is a pharmaceutical and medical device company specializing in the development and commercialization of therapies focused on medical treatments of dermatological conditions. We believe our focus on dermatologic conditions sets us apart as a company that understands the growing needs of the dermatology specialty. Our commitment is to be best-in-class in skin-related therapies, providing clinicians with improved solutions for the management of daily challenges experienced in their practice.
News from Innocutis:
Innocutis Introduces Dexter the Dystrophic Nail to Educate the Public on Nail Dystrophy and How Nuvail Can Help Treat This Common Problem
CHARLESTON, S.C., April 16, 2014 /PRNewswire/ — Innocutis, a specialty pharmaceutical company in Dermatologic and Podiatric specialties, is pleased to announce that Nuvail [poly-ureaurethane, 16%] is currently the #1 Prescribed Brand for Nail Dystrophy in both dermatology and podiatry. Nail Dystrophy affects a vast portion of the U.S. population and the medical community has had limited […]
Innocutis Holdings LLC Licenses "Sitavig" from BioAlliance Pharma
CHARLESTON, S.C., March 19, 2014 /PRNewswire/ — Innocutis Holdings LLC, an innovative pharmaceutical company dedicated to marketing best-in-class branded prescription products in skin-related therapies, is pleased to announce the licensing of Sitavig® (ACYCLOVIR) 50mg Buccal Tablets, from BioAlliance Pharma for the North American markets. Sitavig represents a breakthrough in the herpes treatment category, which is comprised […]
Innocutis Announces the FDA Approval of Nuvail™ (Poly-Ureaurethane, 16%) for the Treatment of Nail Dystrophy
CHARLESTON, S.C., Sept. 18, 2012 /PRNewswire/ — Innocutis is pleased to announce the FDA approval of Nuvail™ (poly-ureaurethane, 16%) nail solution, a novel prescription product to help manage fragile, damaged or brittle nails with cracking or splitting, a condition medically referred to as "nail dystrophy." (Photo: http://photos.prnewswire.com/prnh/20120918/PH75611 ) Among the most common forms of nail dystrophy […]
Innocutis Announces Three New Prescribing Options for BIONECT™
CHARLESTON, S.C., Sept. 18, 2012 /PRNewswire/ — Innocutis is pleased to announce the introduction of three new prescribing options of Bionect® (hyaluronic acid sodium salt, 0.2%): an aqueous base 20ml spray, and aqueous base 100g cream and gel formulations. (Photo: http://photos.prnewswire.com/prnh/20120918/PH75633 ) Available by prescription only, Bionect is formulated using a patented low molecular weight […]
